Mesa Laboratories, Inc. (MLAB) 株式分析

企業概要

Mesa Laboratories, Inc. is engaged in the development, design, manufacturing, sales, and servicing of life sciences tools, quality control products, and services across North America, Europe, the Asia Pacific, and international markets, with a specific offering in sterilization and disinfection control segments including biological, chemical, and cleaning indicators. The company operates within the Technology sector, specifically under the Scientific & Technical Instruments industry, positioning it as a provider of specialized equipment and reagents essential for research and quality assurance applications. Mesa Laboratories, Inc. currently maintains a market capitalization of $512.87M and reported annual revenue of $247.54M based on trailing twelve-month figures, employing a workforce of 730 individuals. These valuation metrics and revenue figures indicate that the company holds a mid-sized position within the specialized instrumentation market, suggesting a solid operational footprint that supports its global distribution network and R&D capabilities.

財務健全性

The company reported revenue of $247.54M, net income of $3.73M, and EBITDA of $42.25M for the trailing twelve months, revealing a significant disparity where net income constitutes only a small fraction of total revenue. This gap highlights a cost structure where high operating expenses, likely driven by R&D investments and global logistics, substantially erode pre-tax profits before reaching the bottom line. Free cash flow stands at $36.83M, which provides the company with substantial financial flexibility to fund ongoing operations, invest in new product development, or service its obligations without relying heavily on external financing. The gross margin is recorded at 62.4%, indicating strong pricing power and high efficiency in the manufacturing and sales of its specialized instruments. The operating margin sits at 12.2%, reflecting the costs associated with research, administration, and distribution, while the profit margin of 1.5% underscores the challenge of converting revenue into actual net earnings. On the balance sheet, cash holdings of $30.47M are significantly lower than total debt of $170.02M, resulting in a debt-to-equity ratio of 91.07, which characterizes the company as highly leveraged relative to its equity base. Despite the high leverage, the current ratio of 1.94 suggests adequate short-term liquidity, as current assets are nearly double the current liabilities. Return on Equity is measured at 2.2% and Return on Assets at 2.5%, metrics that reveal limited management effectiveness in generating substantial returns relative to the capital invested and the asset base employed.

バリュエーション評価

The trailing twelve-month P/E ratio is 145.05, whereas the forward P/E is significantly lower at 17.22, implying that the market expects a dramatic expansion in future earnings that is not reflected in current profitability. The price-to-book ratio stands at 2.75, indicating that the market values the company at a premium of 175% over its net book value, likely due to the intangible value of its intellectual property and brand in the life sciences sector. The price-to-sales ratio is 2.07, and the EV/EBITDA multiple is 15.44, suggesting that the company is valued based on its cash generation capabilities rather than current earnings, which are currently depressed by the high debt load. The 52-week high is $131.20 and the 52-week low is $55.45, providing a historical trading range against which the current valuation can be assessed. The beta value of 0.89 indicates that the stock exhibits lower volatility than the broader market, suggesting it may act as a defensive holding within the technology sector during periods of market turbulence.

Growth & Income

Revenue growth over the last year is 3.6%, while earnings growth is N/A, indicating that the company is currently not generating positive year-over-year earnings growth to report, which constrains the ability to increase dividend payouts sustainably. The dividend yield is 0.7% with a payout ratio of 98.5%, a figure that suggests the company is distributing nearly all of its available earnings to shareholders, leaving little room for retention and reinvestment. Given the N/A status of earnings growth and the extremely high payout ratio, the dividend sustainability is precarious as any slight decline in earnings could threaten the ability to maintain the current payout level. Consequently, the company's income profile is characterized by a high reliance on current earnings for dividend distribution rather than a robust history of growing free cash flow to support increasing payouts.